What is pemetrexed dipotassium?
Pemetrexed dipotassium is the salt form of pemetrexed, a chemotherapy medicine used to treat certain cancers. It is marketed under brand names that include Alimta (pemetrexed). The specific “dipotassium” wording refers to the drug’s chemical salt form used in the finished product.
What cancers is it used for?
Pemetrexed (including the dipotassium salt form) is used for patients with:
- Non-squamous non-small cell lung cancer (NSCLC), typically in combination with a platinum-based chemotherapy partner
- Malignant pleural mesothelioma, often as part of a chemotherapy regimen
How is it usually given?
Pemetrexed is given as an intravenous (IV) infusion, typically on a repeated cycle schedule in combination regimens for lung cancer and mesothelioma (the exact schedule depends on the regimen and treatment line).
Does the “dipotassium” form change how it works?
The clinical activity comes from pemetrexed itself. The “dipotassium” designation describes how the active molecule is formulated as a salt. That salt form helps determine handling and stability of the drug product, but dosing and clinical use are based on pemetrexed exposure as defined for the approved product.
Common patient questions: side effects and precautions
Patients and clinicians commonly discuss pemetrexed-related side effects such as fatigue, nausea, low blood counts, and skin or mucosal irritation. Pemetrexed regimens also typically include folic acid and vitamin B12 supplementation to reduce toxicity, and patients are usually monitored with blood tests before each cycle.
Patents and market information (who makes it, and exclusivity history)
If you’re researching availability, patent status, or generic/biosimilar competition for pemetrexed products (including pemetrexed dipotassium formulations), DrugPatentWatch.com tracks patent and exclusivity information for drugs in the market and can help identify key filing and expiry milestones. You can check it here: DrugPatentWatch.com
Sources
- DrugPatentWatch.com